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(P < 0.0002, chi-square; range from 0.5 to 6.6 events per
100 patient years) conﬁrming signiﬁcant heterogeneity in
the results. In the assembled cohort of 3998 patients there
were 174 admissions in 6 months, of which 117 included
some evidence of warfarin related bleeding. Applying the
criteria from the 12 different studies resulted in a range
of 24 to 117 of these events being classiﬁed as “major
bleeds”. The 3 studies with most restrictive deﬁnitions
reported from 0.5 to 1.1 events per 100 patient years,
compared with from 1.5 to 2.8 events per 100 patient
years for the 4 studies with least restrictive deﬁnitions.
CONCLUSIONS: It is essential for future outcomes
research in anticoagulant therapy that consistent deﬁni-
tions of major adverse outcomes are applied. The in-
consistent deﬁnitions used in the 12 published studies
reviewed make it impossible to assess the impact of other
differences between studies, for example in INR range or
% of time within range.
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OBJECTIVES: To evaluate the effectiveness of the care
provided to patients with heart failure through the im-
plementation of clinical pathways at the hospital “The
Holy Family” in Novafeltria (Italy). METHODS: We per-
formed a pre-post analysis model to evaluate the effect of
the application of clinical pathways on process indicators,
outcome indicators and on the costs sustained to treat the
patients. We compared the results obtained treating the
patients according to the clinical pathway with the results
obtained before implementing the pathway. We studied
quantitative variables with t Student test or Wilcoxon
test, qualitative variables with X2 test. RESULTS: Two
hundred forty-six cases were included in our study. These
subjects were all the patients admitted for hearth failure
to the hospital and treated by the staff. We compared the
age, the sex and the disease staging (NYHA scores at
admission) of the patients of the 2 groups and we did not
ﬁnd any signiﬁcant difference. After the implementation
of the pathway we observed a signiﬁcant improvement of
the core processes. We observed a reduction of the rate
unscheduled readmissions within 31 days from discharge
(from 6.74% to 2.94%; p > 0.05), of the average length
of stay (from 10.89 days to 7.86; p < 0.05) and of inpa-
tients’ mortality (from 17.42% to 4.41%; p < 0.01). The
average costs for patient increased from 2.399 US$ 
to 2.596 US$ (p > 0.05). CONCLUSION: Our primary
ﬁnding was that the implementation of the clinical
pathway for heart failure improved patients’ outcomes
and the quality of the core processes. Our results also
showed that this was possible without incrementing the
costs. This study has important limitations too. The initial
measurement occurred a year before the full implemen-
tation of the pathways. Thus, it is possible that some of
the observed improvement represented a natural drift
toward higher performance.
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OBJECTIVE: To determine the number needed to treat
(NNT) for one additional patient to achieve the European
Atherosclerosis Society (EAS) target for LDL-C of <3
mmol/L at 12 weeks for rosuvastatin compared to ator-
vastatin, pravastatin or simvastatin. Patients included in
the clinical trials comparing rosuvastatin with ator-
vastatin, pravastatin and simvastatin had an initial 
LDL-C ≥160 (4.1mmol/L) and <250mg/dL (6.5mmol/L).
METHODS: The rosuvastatin trials were speciﬁcally
designed to allow pooling of the data to provide summary
estimates of efﬁcacy. This design strategy minimised the
potential bias caused when pooling results by variation in
the event rates, differences in the outcomes considered,
effects of secular trends on disease risk, and differences
in clinical setting. The pooled efﬁcacy data was used as
the basis for the calculation of the NNTs. RESULTS:
Rosuvastatin 10mg is more effective at lowering LDL-C
to the EAS target than atorvastatin 10mg, pravastatin 20
mg and simvastatin 20mg at 12 weeks and this translates
into relatively small NNTs. By convention, NNTs are
rounded up to the nearest whole number of patients.
Rosuvastatin 10mg has an NNT of 4 compared to ator-
vastatin 10mg, 2 compared to pravastatin 20mg, and 4
compared to simvastatin 20mg (p < 0.001, all compar-
isons). CONCLUSIONS: As a general rule, an NNT of 6
or less might be considered “good” for an acute treat-
ment, while an NNT as large as 40 might be considered
“good” for a chronic treatment (depending on the dura-
tion of treatment and the severity of outcome). In this
context, an NNT of 4 for rosuvastatin 10mg compared
to the next best in class (atorvastatin 10mg) would be
considered a very favourable result.
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OBJECTIVES: Enoxaparin has been used for thrombo-
prophylaxis (TBX) when patients with mechanical heart
valves require bridging therapy for sub-therapeutic
chronic oral anticoagulation (COA). Due to recent
